ES2796476T3 - Procedimiento para la producción de una forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona - Google Patents

Procedimiento para la producción de una forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona Download PDF

Info

Publication number
ES2796476T3
ES2796476T3 ES17711562T ES17711562T ES2796476T3 ES 2796476 T3 ES2796476 T3 ES 2796476T3 ES 17711562 T ES17711562 T ES 17711562T ES 17711562 T ES17711562 T ES 17711562T ES 2796476 T3 ES2796476 T3 ES 2796476T3
Authority
ES
Spain
Prior art keywords
acid
crystalline form
sodium
luminol
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17711562T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Martin
Josef Breu
Juliane Fleissner
Wolfgang Brysch
Wegerer Jörg Von
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metriopharm AG
Original Assignee
Metriopharm AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metriopharm AG filed Critical Metriopharm AG
Application granted granted Critical
Publication of ES2796476T3 publication Critical patent/ES2796476T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES17711562T 2016-02-16 2017-02-15 Procedimiento para la producción de una forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona Active ES2796476T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16000380 2016-02-16
PCT/EP2017/000209 WO2017140422A1 (en) 2016-02-16 2017-02-15 Method for producing a crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione

Publications (1)

Publication Number Publication Date
ES2796476T3 true ES2796476T3 (es) 2020-11-27

Family

ID=55361317

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17711562T Active ES2796476T3 (es) 2016-02-16 2017-02-15 Procedimiento para la producción de una forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona

Country Status (8)

Country Link
US (1) US11203575B2 (https=)
EP (1) EP3416952B1 (https=)
JP (1) JP6949856B2 (https=)
KR (1) KR102535959B1 (https=)
CN (1) CN109071461B (https=)
CA (1) CA3011766C (https=)
ES (1) ES2796476T3 (https=)
WO (1) WO2017140422A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3511325A1 (en) * 2018-01-11 2019-07-17 MetrioPharm AG Method for solubilizing 5-amino-2,3-dihydro-1,4-phthalazinedione
EP3870175B1 (en) * 2018-10-26 2024-08-28 Immunopharma Plus D.O.O. Oral aminodihydrophthalazinedione compositions and their use the treatment of non-viral hepatitis
EP3858328A1 (en) * 2020-01-31 2021-08-04 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the inhalatory treatment of inflammatory pulmonary diseases
KR20220158030A (ko) * 2020-03-25 2022-11-29 메트리오팜 아게 급성 폐손상 치료용 5-아미노-2,3-디히드로-1,4-프탈라진디온
MX2022015601A (es) * 2020-06-10 2023-01-30 Metriopharm Ag Compuesto para el tratamiento de infecciones coronavirales.
JP2023553290A (ja) * 2020-12-01 2023-12-21 リバースパ エルエルシー 慢性閉塞性肺疾患、喘息、肺炎、気管支炎、嚢胞性線維症、肺水腫、間質性肺疾患、サルコイドーシス、特発性肺胞線維症、急性呼吸窮迫症候群、および肺動脈性肺高血圧症を治療するための方法および組成物
CN116963738A (zh) * 2020-12-02 2023-10-27 麦翠奥制药公司 用于SARS-CoV-2感染的后遗症的预防和治疗的鲁米诺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743541A (en) * 1985-07-17 1988-05-10 Mast Immunosystems, Inc. Luminescent substrate preparation and its use in specific binding assays
FR2839155B1 (fr) * 2002-04-25 2005-02-04 Roc Imp Procede pour detecter et localiser des traces de sang et compose pour detecter des traces de sang
BRPI0307864B1 (pt) * 2003-11-25 2016-01-12 Univ Rio De Janeiro processo para formação de hidrazidas a partir de hidrazinas e ácido dicarboxílicos
CN100390152C (zh) * 2006-03-23 2008-05-28 潘健 一种合成3-硝基或3-氨基邻苯二甲酰肼的方法
PL231885B1 (pl) * 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
ES2487221T3 (es) * 2010-03-01 2014-08-20 Metriopharm Ag Formas cristalinas de 5-amino-2,3-dihidroftalazina-1,4-diona sal sódica (sal sódica 5-amino-2,3-dihidroftalazina-1,4-diona), preparados farmacéuticos que la contienen y método de producción
US20110246075A1 (en) * 2010-04-01 2011-10-06 Banik Niranjan C Providing a Transform Function to Produce a Mechanical Property of a Subterranean Structure
WO2011123776A2 (en) * 2010-04-01 2011-10-06 Guthery B Eugene Method for detecting occult blood

Also Published As

Publication number Publication date
JP2019504865A (ja) 2019-02-21
KR20180107278A (ko) 2018-10-01
CN109071461B (zh) 2022-06-21
CA3011766C (en) 2023-08-01
KR102535959B1 (ko) 2023-05-23
US11203575B2 (en) 2021-12-21
JP6949856B2 (ja) 2021-10-13
WO2017140422A1 (en) 2017-08-24
CA3011766A1 (en) 2017-08-24
EP3416952B1 (en) 2020-04-08
CN109071461A (zh) 2018-12-21
EP3416952A1 (en) 2018-12-26
US20200369623A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
ES2797299T3 (es) Forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona
ES2796476T3 (es) Procedimiento para la producción de una forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona
ES2880500T3 (es) Composiciones farmacéuticas que contienen nitrito de sodio
ES2753577T3 (es) Forma cristalina de 5-amino-2,3-dihidroftalazina-1,4-diona sal sódica, los preparados farmacéuticos que la contengan y método de producción
EP3248602A1 (en) Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
CN111295369B (zh) 碳酸加合物
KR102687603B1 (ko) 공결정, 이의 제조방법 및 공결정을 함유하는 의약
EP4178579B1 (en) 5-amino-2,3-dihydro-1,4-phthalazinedione as glucocorticoid-sparing agent
JP7807378B2 (ja) 稀な慢性炎症性肺疾患の治療における5-アミノ-2,3-ジヒドロ-1,4-フタラジンジオンの使用
HK40001510B (en) Method for producing a crystalline form of 5-amino-2, 3-dihydrophthalazine-1, 4-dione
HK40001510A (en) Method for producing a crystalline form of 5-amino-2, 3-dihydrophthalazine-1, 4-dione
HK40001511A (en) Crystalline form of 5-amino-2,3-dihydrophtalazine-1,4-dione